Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update
25 Julio 2024 - 3:05PM
Business Wire
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global
biopharmaceutical company focused on developing differentiated
molecules and combination therapies for people with cancer,
announced that its management team will host a conference call and
webcast on Thursday, August 8th, 2024 at 2 PM PT / 5 PM ET to
discuss details of the Company’s financial results and pipeline
update for the quarter ended June 30th, 2024.
Investors interested in listening to the conference call may do
so by dialing (404) 975-4839 (local) or (833) 470-1428 (toll-free),
using Access Code: 287576. To access the live webcast and
accompanying slide presentation, please visit the “Investors &
Media” section of the Arcus Biosciences website at
www.arcusbio.com. A replay of the webcast will be available
following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical
company developing differentiated molecules and combination
medicines for people with cancer. In partnership with industry
collaborators, patients and physicians around the world, Arcus is
expediting the development of first- and best-in-class medicines
against well-characterized biological targets and pathways and
studying novel, biology-driven combinations that have the potential
to help people with cancer live longer. Founded in 2015, the
company has expedited the development of multiple investigational
medicines into clinical studies, including new combination
approaches that target TIGIT, PD-1, the adenosine axis (CD73 and
dual A2a/A2b receptor), HIF-2a, CD39 and AXL. For more information
about Arcus Biosciences’ clinical and pre-clinical programs, please
visit www.arcusbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240725633260/en/
Investor Inquiries Pia Eaves VP of Investor Relations
& Strategy (617) 459-2006 peaves@arcusbio.com
Media Inquiries Holli Kolkey VP of Corporate
Communications (650) 922-1269 hkolkey@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Arcus Biosciences (NYSE:RCUS)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
